A major milestone in epigenomics has been reached as Epigenica AB announced a new partnership with Swedish National Genomics Infrastructure (NGI), part of SciLifeLab.

 

NGI has become the first certified core laboratory and service provider worldwide to offer Epigenica’s EpiFinder platform.

 

The designation marks a significant expansion in access to high-throughput, multiplex epigenomic profiling technologies for researchers globally.

 

Under the agreement, NGI will deliver full end-to-end workflows using both EpiFinder cNUC and EpiFinder GenomePro. These systems enable scalable profiling of histone modifications and DNA methylation in circulating nucleosomes, cells, tissues, plasma, and serum—supporting reproducible, high-resolution epigenomic analysis across study sizes.

 

“Partnering with NGI marks the first step in scaling access to our epigenomic platforms,” said Mohamad Takwa, CEO of Epigenica. 

 

“By working with one of Europe’s leading genomics infrastructures, we are not only expanding availability of EpiFinder GenomePro and EpiFinder cNUC, but also establishing a model for how these technologies can be deployed more broadly. This collaboration lays the foundation for a growing network of partners and will support more consistent, high-quality epigenomic research at scale.”

 

Researchers using NGI’s services will gain access to both platforms, along with integrated project support spanning study design, sample preparation, sequencing, and downstream bioinformatics analysis.

 

“We are thrilled to be the first core facility certified to deliver Epigenica’s EpiFinder technologies,” said Anja Mezger, Head of Unit at NGI in Stockholm. 

 

“These platforms fill critical needs for researchers seeking high resolution epigenomic insights through streamlined workflows. With EpiFinder GenomePro and cNuc, we can offer even greater depth and capability within our service portfolio.”

 

The collaboration forms part of Epigenica’s broader strategy to build a global network of certified service providers delivering standardized, high-quality epigenomic data. The company says additional partner sites will be announced as adoption of its EpiFinder technologies expands across academia and biopharmaceutical research.